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Abstract 
Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a 
rare and a very rare uro-genital cancers, respectively. Both tumours are well defined 
entities in terms of management, where specific recommendations - in the form of 
continuously up-to-dated guide lines - are provided. 
Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the 
beginning of their adult life. PeSCC affects older men, but a proportion of these patients 
are young and the personal consequences of the disease may be devastating 
Deviation from recommended management may be a reason of a significant prognostic 
worsening, as proper treatment favourably impacts on these tumours, dramatically on GCT 
and significantly on PeSCC. 
RARECAREnet data may permit to analyse how survivals may vary according to 
geographical areas, histology and age, leading to assume that non-homogeneous health-
care resources may impact the cure and definitive outcomes. In support of this hypothesis, 
some epidemiologic datasets and clinical findings would indicate that survival may improve 
when appropriate treatments are delivered, linked to a different accessibility to the best 
health institutions, as a consequence of geographical, cultural and economic barriers.  
Finally, strong clues based on epidemiological and clinical data support the hypothesis that 
treatment delivered at reference centres or under the aegis of a qualified multi-institutional 
network is associated with a better prognosis of patients with these malignancies.  
The ERN EURACAN represents the best current European effort to answer this clinical 
need.  
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Introduction 
Among rare solid tumour of the male genital tract, testicular and penile cancers deserve a 
special interest due to their particular characteristics, although they show significant 
epidemiological differences.  
Testicular tumours basically affect young men between 20 and 40 year-old, at the 
beginning or in full employment, social and affective life (1), 2), 3), 4), 5). The annual 
incidence of testicular and para-testicular tumours is 3.29 (95% CI 3.27-3.32) cases per 
105 individuals, corresponding to 16,061 new cases in 2013 in EU28  (Error! Reference source 
not found.. The vast majority of these tumours are germ-cell tumours (GCT), as para-
testicular adenocarcinoma and sex stromal tumours, display a crude incidence of only 
0.001 and 0.02 x 105 individuals (Error! Reference source not found., respectively. Following 
histological diagnosis, clinical decisions are crucial. Prognosis of GCT dramatically 
changed in the eighties of the past century, following the introduction of extremely effective 
drugs as cisplatin and etoposide, which allowed a cure for more advanced cases. Surgery 
evolved accordingly, and the most important and crucial intervention remains 
retroperitoneal lymph-node dissection (RPLND), which is usually indicated after 
completion of chemotherapy in non-seminoma, in very selected cases in seminoma and in 
some patients before chemotherapy in non-seminoma (1-4).  
Penile cancer usually affects men between the 5th and the 8th decades, associates with 
local chronic inflammation or with human papillomaviruses (HPV) infection of some 
subtypes (mainly HPV 16, 18, 30 and 33) (6), 7). In Europe, the annual crude incidence 
rate of penile cancer is 0.66 (95% CI 0.65- 0.67) cases per 105 individuals, and equals to 
3,887 new cases in 2013 in EU28 (Error! Reference source not found.. Almost all penile 
cancers are penile squamous cell cancer (PeSCC), as adenocarcinoma had a crude 
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incidence rate of 0.01.  The prognosis of this disease is favourable in early stages, the 
most frequent, while it remains dismal in advanced disease, as no highly effective medical 
treatment is available. Surgery (i.e. inguinal and pelvic lymph-node dissection) remains 
crucial for the staging and the cure, as early detected small nodal metastases may be 
cured in more than 60% of cases at 5 years (7-9). 
In common, GCT of the testis (1-4) and PeSCC (6), 7) have defined recommendations, 
summarized by different and consistent guide-lines, both in the diagnosis and in the 
treatment. Theypothesis is that atreatment not delivered according to the guidelines and 
by untrained professionals, may dramatically worsen the prognosis of these diseases .  
This review discusses the burden of these two rare cancers, in term of frequency and 
outcome, focuses on the crucial points for diagnosis and treatments and sustains ongoing 
European efforts to standardise management.  
 
Diagnosis 
1) Clinical presentation. 
a. GCT of the testis. Usual presentation is a tenderless intrascrotal mass, with 
no or just moderate pain. Many patients currently present with a small lesion 
identified by scrotal ultrasound. Although an increasing information pressure 
disseminates the importance of auto-palpation in the young men, many 
patients still present with very large testicular masses, which may associate 
with a greater risk of an advanced disease.  
b. PeSCC. Initial lesions are usually painless. Cultural heritage may impact on 
the individual attitude to access visit for a genital lesion. Diagnosis is often 
delayed due to patient modesty or due to wrong clinical diagnosis.  
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2) Histological diagnosis.  
a. GCT of the testis.  
i. Recently, the International Society of Urological Pathology (ISUP) 
held the Testicular Cancer Consultation Conference and produced 
recommendations to be followed for standardize pathology (11). The 
most critical issues received a recommendation, and often the 
question of a central review is called in. An Italian study showed that 
up to the early 2000’s, half of the reports regarding stage I non-
seminoma patients did not contain the information about vascular 
invasion (12). Moreover, 27% of cases on review at a central 
pathology laboratory were reclassified as having vascular invasion, 
while 19% were reclassified as not having vascular invasion (12). 
Since then, an extensive informative campaign conducted by the 
Italian Germ Cell Testicular Tumour Study Group (13), was able to 
reduce the number of reports with lacking information on vascular 
invasion.  
ii. Intra-operative diagnosis through frozen sections examination. Most 
diagnoses occur following ultrasound examination that reveals a small 
testicular hypoechoic lesion (< 10 mm). The diagnostic pathway often 
includes surgical exploration and open biopsy (13). This pathway may 
spare a useless orchidectomy in case of benign lesions (15). An 
experienced pathologist can provide better performance in terms of 
accordance with definitive pathology (15). Wrong intra-operative 
diagnoses may lead to useless orchiectomy or to a re-operation.  
iii. An emerging interest concerns malignant transformation of teratoma 
(TMT). Cellular atypia of epithelial and mesenchymal elements in 
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teratomatous metastases of patients treated with cisplatin-based 
chemotherapy for non-seminoma have been frequently found, which 
does not necessarily imply a different clinical outcome. Presence of 
only the expansive growth of the somatic malignant proliferation is a 
significant feature for the diagnosis of a TMT (16)16). Although we 
have not an evidence supporting the need of an expert pathologist to 
assure the diagnosis of TMT, the complex evaluation criteria are 
intuitively a reason to recommend a second opinion review, in order to 
reduce misdiagnoses (including over-diagnoses). 
TMT is rare, but associates with a worse prognosis than usual GCT. 
Moreover, the role of surgery both as post-chemotherapy option and 
as primary treatment (RPLND) in early stages of disease is commonly 
recommended, as it is associated with a better outcome (17).   
b.  PeSCC. The recent 2016 WHO classification on penile cancer deeply 
changed (18). Most previous classifications were morphology-based. The 
current one presents a new classification based on clinic-pathologic 
distinctiveness and relation to HPV infection, which may be suspected by the 
analysis of p16 (19). Some histological PeSCC variants associate with 
different clinical behavior. Some have more favorable course than usual 
type, and deserve a more conservative treatment. Other, as sarcomatoid, 
basaloid and acantholytic SCC may have a rapid spread, sometime skipping 
inguinal nodes, and must require more aggressive treatment since the first 
diagnosis.  
 A UK experience (20)  showed that after histology review, pathology 
diagnoses significantly changed, with 31% of cases receiving a 
reclassification. The changes were deemed to be critical in 60.4% cases: 
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some patients required more extensive and invasive treatment for local 
penile cancer management, while a change to a more conservative 
treatment approach in the pathologically downgraded group was provided in 
some cases.  
Although no proof supports a different survival according to central review Vs 
initial report, it is intuitive that an adequate sampling and expert examination 
may give more detailed information about variants, invasion and extent of 
invasion beyond lamina propria, which play a prognostic role and may permit 
organ preservation and better quality of life in many patients.  
 
Treatment of primary tumour 
1) GCT of the testis.  
a. Radical orchiectomy is the standard surgery for testicular GCT. Actually, 
about 90% of these simple surgeries are performed in primary care hospitals. 
We have no evidence that centralisation of orchiectomy may produce any 
impact on the outcome of these patients.  
b. Partial orchiectomy. This procedure is called in for mono-orchid patients, 
where maintaining a sufficient amount of testicular parenchyma ensures the 
preservation of patient's own body image and of endocrine function. This 
procedure needs precise surgical steps, although it is not considered 
technically difficult. It requires a cautious evaluation of the preoperative 
functional aspects, the patient expectations in terms of paternity and residual 
function; as a consequence dedicated endocrinologists and/or andrologists 
are advised (21). 
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2) PeSCC. Most early PeSCC may require conservative treatments. Laser excisions 
or surgical excision followed by glans resurfacing and - in some cases - Mohs 
surgery, represent documented effective alternatives with different indications and 
chances (22). In a large mono-institutional series, patients treated with penile 
preservation showed no significant difference in survival compared to patients 
treated with partial amputation after adjusting for relevant co-variables (23). Due to 
the rarity of disease, such procedures usually require dedicated surgeons, with a 
specific expertise.  
Patients with recurrent disease or more advanced stage, need glansectomy or 
amputation. As the primary treatment of high-risk primary tumours temporally 
coincides with the management of inguinal nodes, which is the key treatment in 
PeSCC management (see next paragraph on staging), it is advisable to plan the 
initial surgery in experienced centres.   
Staging following initial surgery 
1) GCT of the testis. Following orchiectomy, staging of testicular GCT includes chest 
and abdominal CT scans with contrast medium and serial determination of serum 
tumour markers AFP and beta unit of human chorionic gonadotropin (β-hCG) (1-4, 
13). Interpretation of imaging is crucial. Smallenlarged lymph-nodes may be 
wrongly interpreted as negative, and may determine an incorrect staging and thus 
inappropriate treatment. Although these imprecisions may hardly be a reason of 
prognostic variations in the short to medium term, they may induce further re-do 
treatments, which associate with a higher risk of late toxicity and late relapses. A 
multidisciplinary team of radiologists and clinicians must accurately evaluate 
imaging of the retroperitoneal space. 
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2) PeSCC. Staging includes palpation of inguinal nodes contextually or soon after 
surgery of the primary tumour. In case of non-palpable nodes, following an 
abdominal and pelvic CT/MRI scans with contrast medium, referral institutions have 
adopted the dynamic sentinel node biopsy (DSNB) (24), 25). This is a multistep 
procedure, which needs a dedicated team of urologists, radiologists, nuclear 
physicians and pathologists. The best results are achieved when each single step is 
correctly performed. A clinical data-set from the Dutch Cancer Institute, reported 
that patients with cN0 disease treated after 1994 showed improved cancer specific 
survival compared to those treated before 1994, when adjusting for pT category and 
grade (26)27). Authors attributed this finding to the early detection of microscopic 
disease by DSNB, resulting in early lymph-node dissection in patients with a tumour 
positive sentinel node. Some evidences showing a trend towards a better survival in 
northern European countries have been reported (27). These findings may support 
to refer patients with initial disease to high-volume experienced centres. 
Surgical treatment of metastatic disease 
The role of surgery remains crucial both in GCT and in PeSCC. The key surgery is lymph-
node dissection, which takes places as prophylactic intervention, primary treatment or 
post-chemotherapy option according to stage. 
1) GCT of the testis.  
a. Prophylactic RPLND. Primary RPLND has been used in early stage non-
seminomatous (NS) GCT of the testis for many years, but it has gradually 
lost its role (28).  In clinical stage I NS-GCT, the extremely favourable 
prognosis as well as the different therapeutic strategies with unaltered 
efficacy - even when they are delayed - led to a progressive reduction of the 
intensity of treatment and to an increasing role of tailored options.  Currently, 
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the recommended policies in these patients are active surveillance or 
adjuvant chemotherapy, consisting in one course of Bleomycin, Etoposide, 
Cisplatin (BEP), while RPLND is no longer suggested as first choice (1-4, 
13). The reasons behind are the morbidity of surgery and, mostly, its low 
reproducibility on a large scale (29). Mini-invasive RPLND (pure laparoscopic 
or robot assisted) has been introduced in order to reduce morbidity of open 
surgery (30). Currently, the available evidences are consistent with a non-
inferiority of mini-invasive RPLND in respect of open surgery (30), 31). 
However, RPLND – open or mini-invasive - remains a highly technical 
demanding procedure that requires experienced hands in referral centers, in 
order to achieve standardized levels of efficiency.  
b. Primary RPLND in early stage NS-GCT (stage II). RPLND represented the 
only effective therapeutic tool up to the introduction of effective 
chemotherapy, when the disease was limited to the retroperitoneum (32), 34) 
. The chance of definitive cure depended on the burden of disease, which 
could vary from small volume (Stage IIA: < 2 cm), to very large disease 
(Stage II D: > 5 cm), where the chance of definitive cure was low (35). 
Currently, indication of primary RPLND in stage II disease reduced, and 
currently is an option in small volume (Stage II A) disease with normal 
markers after orchiectomy. Other indications, as stage IIB non-seminoma or 
IIA/B seminoma, should be considered within clinical trials (1-4, 13). Expert 
opinions summarised by current guide-lines, recommend this surgery in 
experienced hands (1-4,  13). 
c. Post-chemotherapy RPLND. Surgery is strongly indicated in case of a 
residual mass ≥ 1 cm and normalised markers following completion of 
primary chemotherapy in NSGCT (1-4, 13). Post-chemotherapy RPLND may 
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be modulated, according to extent, volume, laterality and adhesion to other 
organs. A limited dissection in small and unilateral masses reduces the risk 
of retrograde ejaculation; a mini-invasive RPLND (pure laparoscopic or, with 
smaller experiences, robot-assisted) reduces the general morbidity of 
laparotomy (36). On the other hand a maximal RPLND with contextual 
removal of organs involved by the disease and possible reconstructive 
surgery (e.g. vascular prosthesis or grafts) may increase the chance of cure 
in patients with gross masses infiltrating viscera or gross vessels (37). This 
surgery is recommended in high-volume centres and should be performed by 
experienced hands. A better outcome following centralization of cure has 
been documented as far as in 1993 (38). Considering 454 patients treated in 
West Scotland, year of diagnosis, extent of disease and treatment unit (the 
higher in volume Vs other 4), were all significant at regression analysis in 
predicting survival (p < 0.001). In a population-based study including 27,948 
patients from 17 SEER registries (1998-2006), the 10-year testicular cancer 
mortality was derived according to different variables. Among 6,192 patients 
with NSGCT, those who underwent RPLND had a 7-fold greater chance of 
survival than patients who had no RPLND  (p < 0.001) at multivariable 
analysis (39). A population study including 882 patients from (SEER 
database: 1988-1997), showed that the post-operative mortality increased as 
age and stage increased: 0.0%, 0.8% for regional, and 6.0% for metastatic 
disease (p .001) (40). Authors drew attention about the need of referring 
advanced cases to high-volume centres, where the reported mortality was 
lower  (0% for primary and 0.8% for post-chemotherapy RPLND.  
2) PeSCC.  
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a. Prophylactic inguinal lymph-node dissection (ILND). Prophylactic ILND in 
case of clinically not palpable nodes (cN0) associates with a better disease 
control than ILND at relapse (41). Nonetheless, ILND in stage N0, finds no 
more than 20% of patients with nodal disease, and associates with a 
significant morbidity, including lymphoedema and wound infections. Modified 
approaches, including template dissection, selection through individuation of 
risk category or DSNB, have been introduced, but require a specifically 
expertise, as already described for DSNB. 
b. Primary inguino-iliac lymph-node dissection (IILND). This intervention is the 
key treatment in PeSCC, as nodal metastases represent the landmark of 
curability for metastatic disease. Actually, early small nodal metastases 
associate with a 5-year cure rate of 60%, while advanced or pelvic node 
metastases associate with not more than 30%, at the best (6), 7), 8), 9). 
Extent of inguinal dissection is formalised (7), 8), 9). Pelvic dissection is 
generally recommended, and could be omitted in a subset of patients with a 
particularly favourable condition, according to studies performed in high-
volume centres (43), 44).  
c. Post-chemotherapy IILND. These patients had undergone chemotherapy 
due to extent of disease or in the context of a clinical trial. Efficacy of 
chemotherapy prior to surgery has not definitively demonstrated (44). The 
special set of application and the greater difficulties due to desmoplastic 
reaction due to chemotherapy advocate the need of expert surgeons in high-
volume centres.  
Population data in testicular and penile cancers. 
1) Survival analysis, time trends in population-based studies. 
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a. GCT of the testis. 
The EUROCARE-5 study included 56,397 patients recorded from 86 cancer 
registries (CRs), in the period 2000–2007, and followed up through 2008 in 29 
countries (5). Survival remained stable, and was high in most of the countries 
(around 90%). Nonetheless, the 5-year survival was low (<80%) in some 
Eastearn countries. Older patients bearing a non-seminoma had the worse 
prognosis. A previous EUROCARE study (45)focusing on 10-yr survival and 
relapse pattern, evaluated 1.350 testicular cancer cases from 13 population-
based CRs (1987-92) in 9 countries. According to stage distribution, three 
Eastern European countries had the lowest proportion of organ-confined 
disease at presentation. The 10-yr survival was statistically lower for seminoma 
in Estonia (63%) and in Poland (68%) than in referral CRs (two Northern Italian 
provinces: 90%), and for non-seminoma in Estonia (47% Vs 85%). Of interest, 
although relapses associated with survival, French CRs showed the highest 
relapse rates, but the 10-yr survival remained high (85% for seminoma and 83% 
for non-seminoma). These findings induced authors to hypothesize that in 
eastern European populations the lower survival was not due entirely to 
advanced stage at diagnosis, but also to inadequate treatment. The 
unfavourable effect of inadequate treatment on the outcome in testicular cancer, 
due to disparity in accessing cure, may be derived also by population studies 
over-sea. The aforementioned study from Fossa et al 39) found that both 
ethnicity (white Vs non-white) and educational level (a proxy of economic status) 
were associated with prognosis in patients with non-seminoma. The positive 
effect of accessing adequate health facilities can be derived from an English 
study, which evaluated data of patients aged 13–24 years treated during the 
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period 1979 – 2001 by the National Cancer Intelligence Centre (46). The relative 
survival for patients with testicular GCT increased from 84% to 96% between the 
first and last time period (p < 0.001), with a geographical variability that did not 
change after adjusting for deprivation index, used to mitigate the effect of 
economic income.  
b. PeSCC. 
Few datasets are available for penile cancer. The EUROCARE-5 study, 
analysing 10,935 patients from CRs, reported a stable survival during the study 
period from 1999 to 2007 (47). Similarly, data from the US, confirmed no 
substantial time trend survival variation since 1990 in 450 patients from 9 SEER 
CRs (48). Geographic differences of outcome, repeatedly reported  by 
EUROCARE, was confirmed for epithelial tumours of penis also by the 
RARECAREnet project with the highest 5-year survival for the Northern (77%) 
and the lowest in the Eastern European countries (60%) (Error! Reference source 
not found.. The survival rate in northern Europe was assumed to depend on the 
introduction of early detection of inguinal lymph-node metastases through the 
introduction of DSNB, as reported above (26), 27), 42).  
2) Conditional survival: a proxy of effective diagnosis and treatment? 
The conditional survival is the probability to survive at five years being alive 1 or 3 
years after diagnosis. This indicator may be a proxy of timely diagnosis and 
adequate treatment. 
a. GCT of the testis. 
Conditional survivals at 5 years, having survived the 1st year after diagnosis, 
were assessed from the EUROCARE dataset (5). The 5 to 1-yr conditional 
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relative survivals ranged between 95% and 97% in almost all areas and 92% in 
eastern European countries. As previously reported, we showed that in some 
Eastern countries initial stage was more advanced than in others. This 
observation may also imply that performance in treating patients in the first year 
could be suboptimal, probably due to more difficult accessibility to experienced 
centres.  
PeSCC.  
From the EUROCARE-5 dataset a 5-yr survival of 68%, with a 1-year conditional 
survival of 80% are derived (5). Considering conditional survivals figures, 
geographical differences markedly reduced. The greater increase between 5-
year survival and conditional survival was however recognised for the Eastern 
European countries, indicating that many advanced and complex cases died 
during the first year after diagnosis.  
3) Centralization and networking 
a. GCT of the testis. 
Dutch researchers, evaluating data between 1989 and 2009 from the 
Eindhoven Cancer Registry (ECR), reported an improvement of 5-yr relative 
survival in all the age-categories except for patients older than 60 years (49). 
According to stage, a significant survival improvement was observed for 
seminoma with regional metastases: the 5-yr relative survival shifted from 
93% in 1989-93 to 100% in 2004-9 (p = 0.01). Relevant improvement trends 
in 5-yr relative survival were recorded for metastatic non-seminoma and for 
metastatic seminoma, as they improved from 78% to 85% (p= 0.05), and 
from 73 to 88% (p = 0.07), respectively. The authors assumed that this was 
probably due to improved chemotherapy and to the referral of patients with 
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metastasized cancer to specialized centres as well as to the improvements 
of the post-chemotherapy RPLND, reasonably associated with centralization 
of more complex cases.  
In 2006, the German Testicular Cancer Study Group started an evidence-
based national second-opinion network in order to improve the care of 
testicular cancer patients: 1,284 requests were submitted by 350 primary 
care physicians to the 31 second-opinion centres from November 2006 to 
October 2011 (50)50). The first-opinion therapy suggested by the advice 
seeker was concordant with the second-opinion therapy recommended by 
the centres in 58% of the cases. Discordance between first and second 
opinions was found in 39.5%. Metastatic cases were those at lower 
concordance. The second-opinion treatment was less extensive in 28.1% 
and more extensive in 15.6% of the discordant cases than that originally 
planned. In another 56.3% of the cases, there was no substantial difference. 
Actual delivered treatment did not adhere with any opinion in as many as 
30% of patients; 85% of the remaining underwent a treatment more adherent 
to second opinion. No data are available regarding outcomes. 
The Italian Germ Cell Study Group (IGG) was founded in 2005 with the aims 
of spreading information regarding testis cancer, through a series of 
divulgation events, and improving the prognosis of patients, by sharing 
complex cases, addressing patients to high volume centres for highly 
specialized treatment (13)13). Moreover, IGG promoted both patients 
lobbying in order to facilitate information and patients advocacy, in order to 
warrant patients rights in their work activities. A measurable effect was that 
of having improved the quality of histological reports of germ-cell tumours. 
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Recently, a position paper supporting the need of centralization has been 
released (51). Authors recognize that it is impossible to find the highest 
evidence supporting improved outcomes on the basis of institutional volume 
alone, but indirect available data and expert consensus support improved 
outcomes in testicular cancer being achieved at high-volume centres and 
through collaborative groups. A call upon six interventions by all the stake-
holders including clinicians, researchers, health-providers, payers, media 
operators and patients is proposed (51).Hospital volume analysis was 
performed from the RARECAREnet in 7 European countries covered by 
registration (Error! Reference source not found.. Centralisation of patients with 
testicular tumours was in general low during the period 2000-2007. Bulgarian 
registry showed that 75% of patients were treated in 19 different hospitals 
with a mean annual admission volume (MAV) for testicular tumour of 12 
cases. Nonetheless, in Belgium and in the Netherlands, more centres (40 
and 42, respectively) treated the 75% of patients with a MAV of 8 and 18, 
respectively. In these countries survival of testis cancer was high, regardless 
of the decentralisation and low MAV. This may depend on the presence of an 
effective network which permits to share patients according to a national 
management guide-lines and by the country public health investment for 
cancer. 
b. PeSCC 
The Dutch experience probably offered the best example of how a leading 
centre (the National Cancer Institute in Amsterdam in this country), may 
favourably impact in a medium size country through its long experience in 
clinical practice and research (52)51). Mortality gradually decreased from 
1959 to 2006, and the percentage of missing stages decreased significantly 
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from 15% in 1989–1994 to 9% in 2001–2006 (p < 0.001). These findings 
may be due to diagnostic anticipation and to the diffusion of effective staging 
procedures, mainly DSNB, which may favourably impact the prognosis of 
PeSCC. Actually, according to the hospital volume analysis from the 
RARECAREnet data (Error! Reference source not found., centralization of 
PeSCC was very low in all the countries with the exception of the 
Netherlands and Slovenia. 
Another positive example of networking is offered by the creation of networks 
specialised in penile cancer in UK. The experience of the supra-network 
multidisciplinary team in reviewing histology e redirecting treatment has been 
reported above (20). In 2012, the first results of the network in the East 
Midlands in UK showed an increase in the number of cases discussed since 
its formation and a trend towards more conservative surgery (53).  
Networking at EU level 
As we argumented, the management of testis and penile cancers poses significant 
diagnostic challenges, sometimes with major consequences for patients’ quality of life and 
outcome. Medical expertise can be difficult to find because of the rarity of the diseases, 
and many patients may migrate from country to country in search of appropriate care. 
Inappropriate management may result in an increased risk of relapse, and risk of death 
due to cancer or other causes which can be treatment-related.  
In order to improve patients referral across EU countries, at EU level the European 
Reference Networks (ERNs) have been established. The ERNs, three of which are 
specifically devoted to rare cancers, have been conceived by the EU Commission as a 
means to provide “highly specialised healthcare for rare or low-prevalence complex 
diseases”. The ERN EURACAN covers all rare adult solid tumour cancers, grouping them 
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into 10 domains corresponding to the RARECAREnet list (11). One of this domain is rare 
urological cancers and includes testicular cancer only.  
The core business of ERNs is to provide multidisciplinary. In addition, the ERNs are meant 
to generate and disseminate knowledge on rare cancers, promote medical education and 
patient’s information, produce clinical practice guidelines and foster research as well as 
epidemiological surveillance. 
  
Conclusions  
Population based studies showed survival differences across countries for these two rare 
cancers. It means that there is room for improvement thus for an European overall 
progress. The formal activation of ERNs is a cornerstone in the EU cooperation on rare 
cancers, and the Joint Action on rare Cancers (JARC) will be instrumental to make them 
grow up the best way possible. Actually, JARC aims at optimizing the process of creation 
of the ERNs, by providing them with operational solutions and professional guidance in the 
areas of quality of care, epidemiology, research and innovation, education and state of the 
art definition on prevention, diagnosis and treatment of rare cancers.  
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